Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
35.05
+3.13 (9.81%)
Nov 24, 2025, 4:00 PM EST
Bayer Aktiengesellschaft Employees
Bayer Aktiengesellschaft had 91,864 employees as of December 31, 2024. The number of employees decreased by 5,067 or -5.23% compared to the previous year.
Employees
91,864
Change (1Y)
-5,067
Growth (1Y)
-5.23%
Revenue / Employee
$608,058
Profits / Employee
-$2,625
Market Cap
34.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 91,864 | -5,067 | -5.23% |
| Dec 31, 2023 | 96,931 | -991 | -1.01% |
| Dec 31, 2022 | 97,922 | 1,972 | 2.06% |
| Dec 31, 2021 | 95,950 | -5 | -0.01% |
| Dec 31, 2020 | 95,955 | -2,782 | -2.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
Bayer Aktiengesellschaft News
- 22 hours ago - DAX Remains Positive Despite Coming Off Early Highs; Bayer Soars Nearly 10% - Nasdaq
- 22 hours ago - European Stocks Gain With Boost From Dovish Fed Comments, Bayer - Financial Post
- 22 hours ago - Bayer stock jump 9% as stroke drug trial revives confidence in pipeline - Invezz
- 23 hours ago - Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer - The Wall Street Journal
- 23 hours ago - Bayer’s stock is jumping on secondary stroke drug’s trial success - MarketWatch
- 1 day ago - Bayer shares up more than 8% on revived fortunes for blood thinner - Reuters
- 1 day ago - Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment - WSJ
- 1 day ago - Bayer's Asundexian Meets Primary Goals In Phase III Study In Secondary Stroke Prevention - Nasdaq